David Bai, PharmD

February 10, 2019

Five-year results from the extended randomized MGTX trial demonstrated that the addition of thymectomy to prednisone leads to long-lasting lower quantitative myasthenia gravis (QMG) scores and prednisone dosing.

February 09, 2019

Molecular minimal residual disease (MRD) testing during the first 4 days of induction therapy does not differentiate responders and nonresponders and should not be used in predicting clinical response for patients with acute myeloid leukemia (AML), according to the results from a recent study.

February 09, 2019

Results from a recent study showed that only age affects cortical thickness or volume, and intracranial volume affects cortical volume in migraine.

February 07, 2019

Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.

February 03, 2019

According to a recent study, the out-of-pocket clinical costs and capitalized clinical costs per approved drug were both lower for orphan drugs compared with nonorphan drugs.

February 02, 2019

Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.

February 02, 2019

A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).

February 02, 2019

A recent study using the 2016 genome-wide association study (GWAS) identified that vascular mechanisms, but also neuronal and metal ion homeostasis, may play a role in migraine susceptibility.

January 27, 2019

Nonheadache and headache specialists have moderate levels of agreement in classifying common chronic headache disorders after using the telephone classification interview model, according to a study.

January 26, 2019

A study of 3 assessments for patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab are examined.